IRAK4, active, GST tagged human
SIGMA/I2785 - PRECISIO® Kinase, recombinant, expressed in baculovirus infected Sf9 cells, ≥70% (SDS-PAGE), buffered aqueous glycerol solution
Synonym: IPD1; NY-REN-64; REN64
Product Type: Chemical
| assay | ≥70% (SDS-PAGE) |
| form | buffered aqueous glycerol solution |
| mol wt | ~81 kDa |
| product line | PRECISIO® Kinase |
| Quality Level | 200 ![]() |
| recombinant | expressed in baculovirus infected Sf9 cells |
| shipped in | dry ice |
| specific activity | 378-512 nmol/min·mg |
| storage temp. | −70°C |
| UniProt accession no. | Q9NWZ3 ![]() |
| Biochem/physiol Actions: | IRAK4 (interleukin-1 receptor-associated kinase 4) protein contains a death domain and a kinase-like domain. IRAKs are mainly involved in toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs) signaling. IRAK4 can activate NF-κB (nuclear factor κ B) and MAPK (mitogen activated protein kinase) pathways. It plays a crucial role in adaptive immunity and inflammatory responses. IRAK4 mRNA levels are higher in humans suffering from Vogt-Koyanagi-Harada (VKH) disease. Mutations in IRAK4 are associated with recurrent pyogenic bacterial infections in children. |
| Legal Information: | PRECISIO is a registered trademark of Merck KGaA, Darmstadt, Germany |
| Physical form: | Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.2 5mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥70% (SDS-PAGE) |
| activity | specific activity: 378-512 nmol/min·mg |
| Storage Temp. | −70°C |
| UNSPSC | 51111800 |

